These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

561 related articles for article (PubMed ID: 19021720)

  • 41. Prognostic factors for therapy-related acute myeloid leukaemia (t-AML)--a single centre experience.
    Suvajdžić N; Cvetković Z; Dorđević V; Kraguljac-Kurtović N; Stanisavljević D; Bogdanović A; Djunić I; Colović N; Vidović A; Elezović I; Tomin D
    Biomed Pharmacother; 2012 Jun; 66(4):285-92. PubMed ID: 22401928
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Haematopoietic cell transplantation with non-myeloablative conditioning in Denmark: disease-specific outcome, complications and hospitalization requirements of the first 100 transplants.
    Kornblit B; Masmas T; Madsen HO; Ryder LP; Svejgaard A; Jakobsen B; Sengeløv H; Olesen G; Heilmann C; Dickmeiss E; Petersen SL; Vindeløv L
    Bone Marrow Transplant; 2008 May; 41(10):851-9. PubMed ID: 18246114
    [TBL] [Abstract][Full Text] [Related]  

  • 43. High antileukemic efficacy of an intermediate intensity conditioning regimen for allogeneic stem cell transplantation in patients with high-risk acute myeloid leukemia in first complete remission.
    Schmid C; Schleuning M; Hentrich M; Markl GE; Gerbitz A; Tischer J; Ledderose G; Oruzio D; Hiddemann W; Kolb HJ
    Bone Marrow Transplant; 2008 Apr; 41(8):721-7. PubMed ID: 18176613
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Differential prognostic impact of pretransplant comorbidity on transplant outcomes by disease status and time from transplant: a single Japanese transplant centre study.
    Kataoka K; Nannya Y; Ueda K; Kumano K; Takahashi T; Kurokawa M
    Bone Marrow Transplant; 2010 Mar; 45(3):513-20. PubMed ID: 19684632
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Long-term follow-up of autologous stem cell transplantation after intensive chemotherapy in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
    Ducastelle S; Adès L; Gardin C; Dombret H; Prébet T; Deconinck E; Rio B; Thomas X; Debotton S; Guerci A; Gratecos N; Stamatoullas A; Fegueux N; Dreyfus F; Fenaux P; Wattel E
    Haematologica; 2006 Mar; 91(3):373-6. PubMed ID: 16531261
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cytogenetics and comorbidity predict outcomes in older myelodysplastic syndrome patients after allogeneic stem cell transplantation using reduced intensity conditioning.
    Yucel OK; Saliba RM; Rondon G; Ahmed S; Alousi A; Bashir Q; Ciurea SO; Popat U; Khouri I; Marin D; Rezvani K; Kebriaei P; Shpall EJ; Champlin RE; Oran B
    Cancer; 2017 Jul; 123(14):2661-2670. PubMed ID: 28324640
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation.
    Wong R; Shahjahan M; Wang X; Thall PF; De Lima M; Khouri I; Gajewski J; Alamo J; Couriel D; Andersson BS; Donato M; Hosing C; Komanduri K; Anderlini P; Molldrem J; Ueno NT; Estey E; Ippoliti C; Champlin R; Giralt S
    Biol Blood Marrow Transplant; 2005 Feb; 11(2):108-14. PubMed ID: 15682071
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective study.
    Voso MT; Leone G; Piciocchi A; Fianchi L; Santarone S; Candoni A; Criscuolo M; Masciulli A; Cerqui E; Molteni A; Finelli C; Parma M; Poloni A; Carella AM; Spina F; Cortelezzi A; Salvi F; Alessandrino EP; Rambaldi A; Sica S
    Ann Oncol; 2017 Jul; 28(7):1547-1553. PubMed ID: 28368509
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Autologous hematopoietic stem cell transplantation as an intensive consolidation therapy for adult patients in remission from acute myelogenous leukemia.
    Jung AS; Holman PR; Castro JE; Carrier EK; Bashey A; Lane TA; Nelson CL; Pu M; Messer K; Corringham SM; Ball ED
    Biol Blood Marrow Transplant; 2009 Oct; 15(10):1306-13. PubMed ID: 19747639
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Secondary myelodysplastic syndrome and acute myelogenous leukemia are significant complications following autologous stem cell transplantation for lymphoma.
    Howe R; Micallef IN; Inwards DJ; Ansell SM; Dewald GW; Dispenzieri A; Gastineau DA; Gertz MA; Geyer SM; Hanson CA; Lacy MQ; Tefferi A; Litzow MR
    Bone Marrow Transplant; 2003 Aug; 32(3):317-24. PubMed ID: 12858205
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Myeloablative hematopoietic stem cell transplantation for myelodysplastic syndrome in patients younger than 55 years: impact of comorbidity and disease burden on the long-term outcome.
    Kanamori H; Enaka M; Ito S; Motohashi K; Hagihara M; Oshima R; Sakai R; Fujisawa S; Tanaka M; Fujimaki K; Fujita H; Ishigatsubo Y; Maruta A
    Int J Lab Hematol; 2010 Apr; 32(2):222-9. PubMed ID: 19573175
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Is International Prognostic Scoring System (IPSS) still standard in predicting prognosis in patients with myelodysplastic syndrome? External validation of the WHO Classification-Based Prognostic Scoring System (WPSS) and comparison with IPSS.
    Park MJ; Kim HJ; Kim SH; Kim DH; Kim SJ; Jang JH; Kim K; Kim WS; Jung CW
    Eur J Haematol; 2008 Nov; 81(5):364-73. PubMed ID: 18637029
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Disease burden may identify patients more likely to benefit from second allogeneic hematopoietic stem cell transplantation to treat relapsed acute myelogenous leukemia.
    Hosing C; Saliba RM; Shahjahan M; Estey EH; Couriel D; Giralt S; Andersson B; Champlin RE; De Lima M
    Bone Marrow Transplant; 2005 Jul; 36(2):157-62. PubMed ID: 15937511
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Predictable prognostic factor of CD56 expression in patients with acute myeloid leukemia with t(8:21) after high dose cytarabine or allogeneic hematopoietic stem cell transplantation.
    Yang DH; Lee JJ; Mun YC; Shin HJ; Kim YK; Cho SH; Chung IJ; Seong CM; Kim HJ
    Am J Hematol; 2007 Jan; 82(1):1-5. PubMed ID: 16986129
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evaluation of comorbidities at diagnosis predicts outcome in myelodysplastic syndrome patients.
    Breccia M; Federico V; Latagliata R; Mercanti C; D'Elia GM; Cannella L; Loglisci G; Salaroli A; Santopietro M; Alimena G
    Leuk Res; 2011 Feb; 35(2):159-62. PubMed ID: 20594593
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Early related or unrelated haematopoietic cell transplantation results in higher overall survival and leukaemia-free survival compared with conventional chemotherapy in high-risk acute myeloid leukaemia patients in first complete remission.
    Basara N; Schulze A; Wedding U; Mohren M; Gerhardt A; Junghanss C; Peter N; Dölken G; Becker C; Heyn S; Kliem C; Lange T; Krahl R; Pönisch W; Fricke HJ; Sayer HG; Al-Ali H; Kamprad F; Niederwieser D;
    Leukemia; 2009 Apr; 23(4):635-40. PubMed ID: 19151786
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Anti-leukaemic role of acute GvHD after unrelated haematopoietic stem cell transplantation in intermediate- to high-risk acute myelogenous leukaemia.
    Kim HJ; Min WS; Eom KS; Cho BS; Kim SY; Bok JN; Kim KS; Min CK; Lee S; Cho SG; Kim DW; Lee JW; Kim CC
    Bone Marrow Transplant; 2007 Dec; 40(11):1069-74. PubMed ID: 17922041
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Usefulness of hematopoietic cell transplantation-specific comorbidity index after allogeneic hematopoietic stem cell transplantation].
    Fujimaki K; Sakai R; Fujisawa S; Fujita H; Tanaka M; Hagihara M; Koharazawa H; Miyazaki T; Tomita N; Kanamori H; Maruta A; Ishigatsubo Y
    Gan To Kagaku Ryoho; 2008 Jan; 35(1):87-91. PubMed ID: 18195534
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The hematopoietic cell transplantation-specific comorbidity index fails to predict outcomes in high-risk AML patients undergoing allogeneic transplantation--investigation of potential limitations of the index.
    Birninger N; Bornhäuser M; Schaich M; Ehninger G; Schetelig J
    Biol Blood Marrow Transplant; 2011 Dec; 17(12):1822-32. PubMed ID: 21708108
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Isolated trisomy of chromosomes 8, 11, 13 and 21 is an adverse prognostic factor in adults with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B 8461.
    Farag SS; Archer KJ; Mrózek K; Vardiman JW; Carroll AJ; Pettenati MJ; Moore JO; Kolitz JE; Mayer RJ; Stone RM; Larson RA; Bloomfield CD
    Int J Oncol; 2002 Nov; 21(5):1041-51. PubMed ID: 12370753
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.